HealthlineStopping Ozempic, Wegovy May Reverse Cardiovascular Benefits

GLP-1 discontinuation is common — 26% of patients in this 333,687-veteran study stopped within 3 years, often due to cost, side effects, or supply issues. This BMJ Medicine study quantifies what clinicians have suspected: stopping GLP-1 therapy doesn’t just reverse weight loss, it reverses cardiovascular protection, and faster than expected.

Clinical Considerations

• Continuous GLP-1 use over 3 years reduced major cardiovascular events by 18% compared to sulfonylurea users; discontinuation erodes that benefit rapidly
• A 6-month interruption alone increased cardiovascular event risk by 4% to 8% compared to continuous users
• Discontinuation of 1 to 2 years without resuming raised cardiovascular risk by 14% to 22%
• Patients who stopped within 18 months saw no significant cardiovascular risk reduction at all, suggesting a minimum duration threshold for meaningful benefit
• Cardiovascular protection appears multi-mechanistic: blood sugar control, blood pressure reduction, anti-inflammatory effects, and direct vascular protection all contribute beyond weight loss alone

Practice Applications

• Counsel patients before they stop: frame GLP-1 therapy as chronic disease management, not a short course, using specific risk numbers from this study
• Prioritize continuity for high cardiovascular risk patients: those with established CVD, diabetes, or multiple cardiometabolic risk factors face the steepest consequences from interruption
• Address discontinuation barriers proactively: cost, side effects, and supply shortages are the leading reasons patients stop; anticipate these at initiation and at each follow-up
• Document cardiovascular risk conversations when patients elect to discontinue, particularly if they have not yet reached 18 months of continuous use

More in Cardiovascular Risk